ARTICLE | Company News
Quark, Pfizer deal
May 7, 2012 7:00 AM UTC
Quark and Pfizer amended a 2006 deal granting the pharma exclusive, worldwide rights to PF-655. Under the amendment, Quark will conduct a Phase IIa trial to evaluate PF-655 in patients with moderate ...